¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"fructose tolerance test2"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • organ tolerance dose
    ±â°ü°ßµõ¼±·®
  • oxygen tolerance
    »ê¼Ò³»¼º
  • self-tolerance
    1. ÀÚ°¡°ü¿ë 2. ÀÚ°¡³»¼º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heat tolerance
    ³»¿­¼º
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º°Ë»ç
  • high-dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • high-zone tolerance
    Ç׿ø°ú·®Çã¿ë
  • immunologic tolerance
    ¸é¿ª°ü¿ë
  • induction tolerance
    ¸é¿ª°ü¿ëÀ¯¹ß
  • low-dose tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • low-zone tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ
  • metabolic tolerance
    ´ë»ç³»¼º
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´çºÎÇϰ˻ç
  • pharmacodynamic tolerance
    ¾à¿ªÇг»¼º
  • pressure tolerance
    ¾Ð¹Ú³»¼º
  • self-tolerance
    ÀÚ°¡°ü¿ë¼º
  • self tolerance
    ÀÚ±â¸é¿ªÇã¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acceleration tolerance
    °¡¼Ó³»¼º(Ê¥áÜ Ò±àõ)
  • acquired tolerance
    ÈÄõ(¼º) ³»¼º(¡­Ò±àõ), ȹµæ°ü¿ë.
  • acquired tolerance
    ȹµæ°ü¿ë, ÈÄõ¼º°ü¿ë
  • altimeter tolerance
    ³»°í¼Ò¼º(ËÀË­ËÛËÛ).
  • galactose tolerance test
    °¥¶ôÅ佺ºÎÇÏ ½ÃÇè.
  • genetic tolerance dose
    À¯ÀüÀû ³»·®(¡­Ò±åÖ).
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • glucose tolerance
    ³»´ç·Â(Ò±ÓØæ³).
  • glucose tolerance test
    ´çºÎÇϽÃÇè
  • glucose tolerance test =GTT
    ´çºÎÇϰ˻ç(ÓØÝ¶ùÃËþÞÛ).
  • heat tolerance
    ³»¿­¼º(Ò±æðàõ).
  • heat tolerance
    ³»¿­¼º(ËÀËçËÛ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adoptive tolerance
    ÀÔ¾ç(¸é¿ª)°ü¿ë(ìýåרóæ¹Î°é»).
  • alcohol tolerance
    ¾ËÄڿ󻼺(¡­Ò±àõ).
  • alkali tolerance
    ¾ËÄ®¸®³»¼º(¡­Ò±àõ)
  • altimeter tolerance
    ³»°í¼Ò¼º(ËÀË­ËÛËÛ).
  • antigen tolerance
    Ç׿ø°ü¿ë.
  • autoimmune disease,immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • autoimmune disease,tolerance
    ³»¿ë·Â(Ò®é»æ³)
  • carbohydrate tolerance
    ź¼öÈ­¹°ºÎÇÏ(¡­Ý¶ùÃ), ź¼öÈ­¹°³»Àμº.
  • carbohydrate tolerance test
    ź¼öÈ­¹°ºÎÇϽÃÇè.
  • cortisone glucose tolerance test =CGTT
    ÄÚ¸£Æ¼¼Õ Æ÷µµ´ç ºÎÇϽÃÇè(¡­øã Ô¬ÓØÝ¶ùÃãËúÐ).
  • cross tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • cross tolerance
    ±³Â÷¸é¿ª°ü¿ë
  • cross-tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • diabetes mellitus,oral glucose tolerance test
    °æ±¸´çºÎÇÏ °Ë»ç(ÌèÏ¢ÓØÝ¶ùà ËþÞÛ)
  • drug disposition tolerance
    ¾à¹°ºÐÇØ³»¼º.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lactose tolerance test
    "¶ôÅ佺 ºÎÇϰ˻ç(ݶùÃËþÞÛ), ¶ôÅ佺³»¼º°Ë»ç(Ò±àõËþÞÛ)"
  • phenylalanine tolerance test
    Æä´Ò¾Ë¶ó´Ñ ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • tolerance
    ³»¼º (Ò±àõ)
  • transferred tolerance
    ÀüÀÌ ³»¼º(ï®ì¹Ò±àõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FBP femoral blood pressure; fibrin breakdown product; folate-binding protein; fructose-1, 6-biphosphatas...
FDP fibrin degradation product; fibrinogen degradation product; flexor digitorum profundus; frontodextra...
FDPase fructose-1,6-diphosphatase
FMP faculty mentorship program; first menstrual period; fructose monophosphate
F1P, F-1-P fructose-1-phosphate
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FBP Fructose 1,6-biphosphate
FBPase fructose-1,6-biophosphatases
FDPase Fructose-1,6-diphosphatase
F-1-P Fructose-1-phosphate
GFOR Glucose-fructose oxidoreductase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • median tolerance limit
    ¹Ý¼ö »ýÁ¸ ÇÑ°è ³óµµ
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
  • pain tolerance
    µ¿Åë ³»¼º, ÅëÁõ ³»¼º
    ÂüÀ» ¼ö ÀÖ´Â ÅëÁõÀÇ °¡Àå Å« ¼öÁØ.
  • pharmacodynamic tolerance
    ¾à¿ªÇÐÀû ³»¼º
  • poison tolerance
    µ¶¹° ³»¼º
    Áö¼ÓÀûÀÎ µ¶¼º ¹°Áú¿¡ ÀÇÇØ »ýü°¡ ±× µ¶¼º ¹°Áú¿¡ ÀúÇ×¼ºÀ» ³ªÅ¸³»´Â °Í.
  • tolerance
    ³»¾à¼º, ³»¼º, ³»¿ë·Â, Çã¿ë, °ü¿ë
    1. º¸Åë ¾à¹°À̳ª µ¶¹°ÀÇ ¸¹Àº »ç¿ë·®À» °ßµð¾î ³¾ ¼ö ÀÖ´Â ´É·Â. 2. ÈÄõÀûÀ¸·Î ȹµæµÈ ¾à¹° ³»¼º. ¹Ýº¹ÀûÀÎ µ¿·®ÀÇ »ç¿ë·®¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀÇ °¨¼Ò ȤÀº °°Àº ¹ÝÀÀÀ» ¾ò±â À§Çؼ­ Áõ°¡µÈ »ç¿ë·®À» ¿ä±¸ÇÏ´Â °Í.
  • tolerance span
    Àγ» ±â°£
  • tolerance to antimicrobial
    Ç×±ÕÁ¦ ³»¼º
  • tolerance to high altitude
    °í¼Ò ³»¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
fructose-2,6-bisphosphate 6-phosphatase <enzyme> Do not confuse with fructose-2,6-bisphosphate 2-phosphatase (EC 3.1.3.46)
Registry number: EC 3.1.3.54
Synonym: fdp 6-phosphatase, fru(2,6)p2 6-phosphatase
(26 Jun 1999)
fructose 6-phosphate <biochemistry> A phosphorylated six-carbon sugar formed in the second step of glycolysis by the action of phosphoglucose isomerase on glucose-6-phosphate. In the third step, fructose 6-phospate and ATP are used to create fructose 1,6-biphosphate, ADP and a free hydrogen with the aid of phosphofructokinase.
(08 Mar 2000)
fructose-6-phosphate phosphoketolase <enzyme> Catalyses the conversion of d-fructose 6-phosphate and orthophosphate to acetylphosphate and d-erythrose 4-phosphate and water
Registry number: EC 4.1.2.22
Synonym: f6p phosphoketolase
(26 Jun 1999)
fructose-bisphosphatase <enzyme> An enzyme that catalyses the conversion of d-fructose 1,6-bisphosphate and water to d-fructose 6-phosphate and orthophosphate.
Chemical name: D-Fructose-1,6-bisphosphate 1-phosphohydrolase
Registry number: EC 3.1.3.11
(12 Dec 1998)
fructose-bisphosphate aldolase <enzyme> An enzyme of the lyase class that catalyses the cleavage of fructose 1,6-biphosphate to form dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. The enzyme also acts on (3s,4r)-ketose 1-phosphates. The yeast and bacterial enzymes are zinc proteins. (enzyme nomenclature, 1992) e.c. 4.1.2.13.
Chemical name: D-Fructose-1,6-biphosphate D-glyceraldehyde-3-phosphate-lyase
Registry number: EC 4.1.2.13
(12 Dec 1998)
fructose-diphosphate aldolase <enzyme> An enzyme of the lyase class that catalyses the cleavage of fructose 1,6-biphosphate to form dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. The enzyme also acts on (3s,4r)-ketose 1-phosphates. The yeast and bacterial enzymes are zinc proteins. (enzyme nomenclature, 1992) e.c. 4.1.2.13.
Chemical name: D-Fructose-1,6-biphosphate D-glyceraldehyde-3-phosphate-lyase
Registry number: EC 4.1.2.13
(12 Dec 1998)
fructose intolerance An autosomal recessive fructose metabolism disorder due to deficient fructose-1-phosphate aldolase (ec 2.1.2.13) activity, resulting in accumulation of fructose-1-phosphate. The accumulated fructose-1-phosphate inhibits glycogenolysis and gluconeogenesis, causing severe hypoglycaemia following ingestion of fructose. Prolonged fructose ingestion in infants leads ultimately to hepatic failure and death. Patients develop a strong distaste for sweet food, and avoid a chronic course of the disease by remaining on a fructose- and sucrose-free diet.
(12 Dec 1998)
fructose metabolism, inborn errors Inherited abnormalities of fructose metabolism, which include three known autosomal recessive types: hepatic fructokinase deficiency (essential fructosuria), hereditary fructose intolerance, and hereditary fructose-1,6-diphosphatase deficiency. Essential fructosuria is a benign asymptomatic metabolic disorder caused by deficiency in fructokinase, leading to decreased conversion of fructose to fructose-1-phosphate and alimentary hyperfructosaemia, but with no clinical dysfunction; may produce a false-positive diabetes test.
(12 Dec 1998)
fructose permease <chemical> Fructose-specific enzyme II of phosphoenolpyruvate-dependent phosphotransferase system in e. Coli
(26 Jun 1999)
acoustic tolerance The maximum sound pressure level that can be experienced without producing pain or permanent defect of hearing in a normal individual.
(05 Mar 2000)
bile acid tolerance test A sensitive test of hepatic dysfunction; following oral administration of labelled or unlabelled bile acid, the measured fractional disappearance rate or 10-minute retention is measured.
(05 Mar 2000)
galactose tolerance test A liver function test, based on the ability of the liver to convert galactose to glycogen, measured by the rate of excretion of galactose following ingestion or intravenous injection of a known amount; normally, less than 3 g appear in the urine within 5 hours after the ingestion of 40 g.
(05 Mar 2000)
radiation tolerance The ability of some cells or tissues to withstand ionizing radiation without serious injury. Tolerance depends on the species, cell type, and physical and chemical variables, including radiation-protective agents and radiation-sensitizing agents.
(12 Dec 1998)
pain tolerance The greatest intensity of painful stimulation that an individual is able to tolerate.
(05 Mar 2000)
gamma-tolerance The tolerance of a person or a piece of equipment to forces that develop as a result of acceleration or deceleration.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á